Generic Medicine Info
May be taken with or without food.
Conditions when peristalsis inhibition should be avoided (e.g. constipation, abdominal distension, ileus). Acute ulcerative colitis, acute dysentery characterised by bloody stools and high fever, bacterial enterocolitis caused by Salmonella, Shigella, and Campylobacter; antibiotic-associated colitis, abdominal pain without diarrhoea. Children <4 years (oral solution); <12 years (cap, orodispersible tab); <18 years (patient with irritable bowel syndrome).
Special Precautions
Patients with AIDS, glaucoma, urinary bladder neck obstruction, pyloric obstruction, significant gastric retention, or intestinal statis, risk factors for QT interval prolongation (e.g. congenital long QT syndrome, history of cardiac arrhythmias or other heart conditions, electrolyte abnormalities). Not recommended for long-term treatment. Hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, drowsiness, tiredness, or depressed level of consciousness, if affected, do not drive or operate machinery. Monitoring Parameters Assess for the cause of diarrhoea prior to treatment. Monitor for signs of CNS toxicity (in patients with hepatic impairment).
Adverse Reactions
Significant: Ileus, constipation, abdominal distension, abdominal pain, bloody stool, syncope, ventricular tachycardia. Eye disorders: Rarely, miosis. Gastrointestinal disorders: Flatulence, nausea, dyspepsia, dry mouth, vomiting. General disorders and administration site conditions: Rarely, fatigue. Immune system disorders: Rarely, urticaria, angioedema. Musculoskeletal and connective tissue disorders: Hypertonia. Nervous system disorders: Headache, dizziness, somnolence, stupor, depressed level of consciousness, loss of consciousness, coordination abnormality. Renal and urinary disorders: Rarely, urinary retention. Skin and subcutaneous tissue disorders: Rash. Rarely, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Potentially Fatal: Megacolon, toxic megacolon, cardiac events e.g. QT interval and QRS complex prolongation, torsades de pointes, cardiac arrest. Rarely, anaphylaxis and anaphylactic shock.
Drug Interactions
Increased plasma concentrations with quinidine, ritonavir, gemfibrozil, ketoconazole, and itraconazole. May increase plasma levels of oral desmopressin. May enhance the QTc prolongation and ventricular arrhythmia of QT-prolonging agents.
CIMS Class
ATC Classification
A07DA03 - loperamide ; Belongs to the class of antipropulsives. Used in the treatment of diarrhea.
Disclaimer: This information is independently developed by CIMS based on loperamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in